Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Verseon Presents Data on a New Class of Anti-coagulants at the 8th Biotech Showcase ConferenceVerseon’s co-founder and Vice President of Research and Development, presented preclinical data on the company’s new class of anti-coagulants at the 8th annual Biotech Showcase
By: Verseon Verseon is a technology-based pharmaceutical company that uses their own proprietary and patented computational drug discovery platform to research and develop novel drugs and drug therapies for unmet medical needs. The Company’s new class of oral, highly selective, direct thrombin inhibitors have been proven in preclinical efficacy studies and also show pharmacokinetic profiles suitable for oral dosing. Verseon’ Kita said, “the data we have obtained in our anticoagulant program represents comprehensive preclinical, scientific evidence that Verseon’s compounds have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New Drug) filings for this program.” Forward-Looking Statements: This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," Notes to editors: Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers. www.verseon.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|